Tocainide
- Atc Codes:C01BB03
- CAS Codes:35891-93-1
- PHARMGKB ID:35891-93-1
Table of contents
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Unlabeled Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Genes that may be involved
- Inhibits
- Drug Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Drug combinations
Chemistry
Tocainide Hydrochloride: C~11~H~16~N~2~O.HCl. Mw: 228.72. (1) Propanamide, 2-amino-N-(2,6-dimethylphenyl)-, hydrochloride, (±)-; (2)(±)-Amino-2′,6′-propionoxylidide hydrochloride. CAS-35891-93-1.
Pharmacologic Category
Class Ib Antiarrhythmics. (ATC-Code: C01BB03).
Mechanism of action
Suppresses automaticity of conduction tissue, by increasing electrical stimulation threshold of ventricle, His-Purkinje system, and spontaneous depolarization of ventricles during diastole by direct action on tissues. Blocks both initiation and conduction of nerve impulses by decreasing permeability to sodium ions of neuronal membrane, which results in inhibition of depolarization with resultant blockade of conduction.
Therapeutic use
Suppression and prevention of symptomatic life-threatening ventricular arrhythmias.
Pregnancy and lactiation implications
Use with caution in pregnant women. Contraindicated in nursing women.
Unlabeled use
Trigeminal neuralgia.
Contraindications
Hypersensitivity to tocainide, any component of the formulation, or any local anesthetics of the amide type. Second- or third-degree heart block (except in patients with functioning artificial pacemaker).
Warnings and precautions
Proarrhythmic effects (QTc prolongation) might occur. During first 3 months of therapy, blood dyscrasias can rarely occur. Use with caution in significant renal impairment. Pulmonary fibrosis, interstitial pneumonitis, fibrosing alveolitis, pulmonary edema, and pneumonia reported with use (fatalities occurred). Use with caution in heart failure (may precipitate or exacerbate condition). Electrolyte disturbances, especially hypokalemia or hypomagnesemia, should be corrected. Use with caution in significant hepatic impairment. Antiarrhythmic agents should be reserved for life-threatening ventricular arrhythmias.